Arbutus Biopharma's Third Quarter 2024 Expectations
Arbutus Biopharma Corporation (NASDAQ: ABUS) is gearing up for an important announcement regarding its third quarter financial results and corporate updates. This event is set for a date that remains significant for stakeholders as it represents not only the quantifiable achievements of the company but also the ongoing progress in their mission to develop a functional cure for chronic hepatitis B virus (cHBV) infection.
Announcement Schedule
The company has outlined a clear schedule for when the financial outcomes and corporate insights will be shared. The press release is expected to drop at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET on the same day. This structured timing allows investors and interested parties to react swiftly to the new information.
How to Access the Conference Call
To participate in the conference call, individuals can register via an online link, which will direct them to dial-in instructions. For those who prefer a visual format, a live webcast will also be made available on the company's website. Listening to these announcements is vital for investors looking to understand the financial health and direction of Arbutus Biopharma.
Archived Information
After the live event, an archived version of the webcast will remain accessible on Arbutus’ website. This feature ensures that stakeholders who cannot attend the live event still have the opportunity to catch up on important details and updates.
About Arbutus Biopharma
Arbutus Biopharma Corporation (NASDAQ: ABUS) is primarily engaged in developing innovative treatments for hepatitis B virus infection. Leveraging their expertise in virology, the company is focused on creating therapies that not only address the virus itself but also enhance the immune system's response to it.
Innovative Therapeutics Approach
The company has a robust pipeline featuring a mix of proprietary compounds aimed at providing a functional cure for cHBV infection. One of their notable products, imdusiran (AB-729), is part of ongoing Phase 2a clinical trials and has generated promising clinical data highlighting its effectiveness.
Leadership and Future Outlook
As the company progresses through its trials and develops new drugs, the leadership at Arbutus remains focused on overcoming the challenges associated with hepatitis B. The exploration of new methods, including the oral PD-L1 inhibitor AB-101, demonstrates their commitment in making significant advancements that could lead to meaningful solutions for patients dealing with chronic infection.
Getting in Touch
Investors and media personnel interested in further information can reach out to Lisa M. Caperelli, the Vice President of Investor Relations. Her contact details are readily available, providing a channel for inquiries related to company operations and financial performance.
Frequently Asked Questions
What is the purpose of the upcoming announcement by Arbutus?
The announcement aims to share the third quarter financial results and corporate updates, providing insights into the company's progress.
How can I participate in the conference call?
To join the conference call, you need to register through the provided link, which includes the dial-in details.
Where can I find the webcast after the event?
An archived version of the webcast will be available on Arbutus' website following the event.
What innovations is Arbutus working on?
Arbutus is involved in developing therapeutics, particularly imdusiran and AB-101, aimed at treating chronic hepatitis B virus infections.
Who can I contact for more information?
For inquiries, you can contact Lisa M. Caperelli, Vice President of Investor Relations, for further details regarding the company.
